Abstract
Cancer stem cells (CSC) are a very small subset of all cancer cells and possess characteristics very similar to normal stem cells, in particular, the capacity for self-renewal, multipotency and relative quiescence. These chemo- and radiation resistant cells are responsible for maintaining tumor volume leading to therapy failure and recurrence. In glioblastoma multiforme (GBM), the most common primary intracranial malignancy, glioma stem cells have been implicated as one of the key players in treatment failure. Many novel treatment modalities are being investigated to specifically target this small group of cells. In this review, we shed light on one such targeted therapy, specifically, oncolytic virotherapy, and review the literature to highlight the advances and challenges in designing effective oncolytic virotherapy for glioma stem cells.
Similar content being viewed by others
References
Nowell, P. C. (1993). Foundations in cancer research. Chromosomes and cancer: the evolution of an idea. Advances in Cancer Research, 62, 1–17.
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105–111.
Stupp, R., Mason, W. P., van den Bent, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352, 987–996.
Hamburger, A. W., & Salmon, S. E. (1977). Primary bioassay of human tumor stem cells. Science, 197, 461–463.
Stupp, R., & Hegi, M. E. (2007). Targeting brain-tumor stem cells. Nature Biotechnology, 25, 193–194.
Till, J. E., & Mc, C. E. (1961). A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiation Research, 14, 213–222.
Bruce, W. R., & Van Der Gaag, H. (1963). A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature, 199, 79–80.
Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730–737.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983–3988.
Li, C., Heidt, D. G., Dalerba, P., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Research, 67, 1030–1037.
Prince, M. E., Sivanandan, R., Kaczorowski, A., et al. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104, 973–978.
Chan, K. S., Espinosa, I., Chao, M., et al. (2009). Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 14016–14021.
Fang, D., Nguyen, T. K., Leishear, K., et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Research, 65, 9328–9337.
Bapat, S. A., Mali, A. M., Koppikar, C. B., & Kurrey, N. K. (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Research, 65, 3025–3029.
Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer, 8, 755–768.
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature, 445, 111–115.
Hermann, P. C., Huber, S. L., Herrler, T., et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 1, 313–323.
Eramo, A., Lotti, F., Sette, G., et al. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differention, 15, 504–514.
Tirino, V., Desiderio, V., d’Aquino, R., et al. (2008). Detection and characterization of cd133+ cancer stem cells in human solid tumours. Public Library of Science ONE, 3, e3469.
Singh, S. K., Clarke, I. D., Terasaki, M., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63, 5821–5828.
Reynolds, B. A., & Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science, 255, 1707–1710.
Dahlstrand, J., Collins, V. P., & Lendahl, U. (1992). Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Research, 52, 5334–5341.
Ignatova, T. N., Kukekov, V. G., Laywell, E. D., Suslov, O. N., Vrionis, F. D., & Steindler, D. A. (2002). Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia, 39, 193–206.
Uchida, N., Buck, D. W., He, D., et al. (2000). Direct isolation of human central nervous system stem cells. Proceedings of the National Academy of Sciences of the United States of America, 97, 14720–14725.
Miraglia, S., Godfrey, W., Yin, A. H., et al. (1997). A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood, 90, 5013–5021.
Singh, S. K., Hawkins, C., Clarke, I. D., et al. (2004). Identification of human brain tumour initiating cells. Nature, 432, 396–401.
Eramo, A., Ricci-Vitiani, L., Zeuner, A., et al. (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Differention, 13, 1238–1241.
Kang, M. K., & Kang, S. K. (2007). Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells and Development, 16, 837–847.
Liu, G., Yuan, X., Zeng, Z., et al. (2006). Analysis of gene expression and chemoresistance of cd133+ cancer stem cells in glioblastoma. Molecular Cancer, 5, 67.
Hegi, M. E., Diserens, A. C., Gorlia, T., et al. (2005). Mgmt gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352, 997–1003.
Bi, C. L., Fang, J. S., Chen, F. H., Wang, Y. J., & Wu, J. (2007). chemoresistance of cd133(+) tumor stem cells from human brain glioma. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 32, 568–573.
Salmaggi, A., Boiardi, A., Gelati, M., et al. (2006). Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 54, 850–860.
Bao, S., Wu, Q., McLendon, R. E., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444, 756–760.
Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M. (2000). Engineered herpes simplex virus expressing il-12 in the treatment of experimental murine brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 97, 2208–2213.
Fulci, G., Breymann, L., Gianni, D., et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences of the United States of America, 103, 12873–12878.
Freeman, A. I., Zakay-Rones, Z., Gomori, J. M., et al. (2006). Phase I/II trial of intravenous ndv-huj oncolytic virus in recurrent glioblastoma multiforme. Molecular Therapy, 13, 221–228.
Bar-Eli, N., Giloh, H., Schlesinger, M., & Zakay-Rones, Z. (1996). Preferential cytotoxic effect of newcastle disease virus on lymphoma cells. Journal of Cancer Research and Clinical Oncology, 122, 409–415.
Cassel, W. A., & Garrett, R. E. (1965). Newcastle disease virus as an antineoplastic agent. Cancer, 18, 863–868.
Guha, A., Dashner, K., Black, P. M., Wagner, J. A., & Stiles, C. D. (1995). Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop. International Journal of Cancer, 60, 168–173.
Libermann, T. A., Nusbaum, H. R., Razon, N., et al. (1985). Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature, 313, 144–147.
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. (1998). Reovirus therapy of tumors with activated ras pathway. Science, 282, 1332–1334.
Forsyth, P., Roldan, G., George, D., et al. (2008). A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Molecular Therapy, 16, 627–632.
Markovitz, N. S., Baunoch, D., & Roizman, B. (1997). The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1. The Journal of Virology, 71, 5560–5569.
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Medicine, 1, 938–943.
Markert, J. M., Medlock, M. D., Rabkin, S. D., et al. (2000). Conditionally replicating herpes simplex virus mutant, g207 for the treatment of malignant glioma: results of a phase I trial. Gene Therapy, 7, 867–874.
Markert, J. M., Liechty, P. G., Wang, W., et al. (2008). Phase ib trial of mutant herpes simplex virus g207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular Therapy, 17, 199–207.
Chung, R. Y., Saeki, Y., & Chiocca, E. A. (1999). B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. The Journal of Virology, 73, 7556–7564.
Glorioso, J. C., & Fink, D. J. (2004). Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annual Review of Microbiology, 58, 253–271.
Rainov, N. G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Human Gene Therapy, 11, 2389–2401.
Phuong, L. K., Allen, C., Peng, K. W., et al. (2003). Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Research, 63, 2462–2469.
Puumalainen, A. M., Vapalahti, M., Agrawal, R. S., et al. (1998). Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Human Gene Therapy, 9, 1769–1774.
Lang, F. F., Bruner, J. M., Fuller, G. N., et al. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. Journal of Clinical Oncology, 21, 2508–2518.
Heise, C., Hermiston, T., Johnson, L., et al. An adenovirus e1a mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Medicine, 6, 1134–1139.
Alemany, R., Balague, C., & Curiel, D. T. (2000). Replicative adenoviruses for cancer therapy. Nature Biotechnology, 18, 723–727.
Jiang, H., Conrad, C., Fueyo, J., Gomez-Manzano, C., & Liu, T.J. Oncolytic adenoviruses for malignant glioma therapy. Frontiers in Bioscience, 8, d577–588.
Lin, E., & Nemunaitis, J. (2004). Oncolytic viral therapies. Cancer Gene Therapy, 11, 643–664.
Lamfers, M.L., Grill, J., Dirven, C.M., et al. Potential of the conditionally replicative adenovirus ad5-delta24rgd in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Research, 62, 5736–5742.
Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., & Alemany, R. (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clinical Cancer Research, 7, 120–126.
Fueyo, J., Gomez-Manzano, C., Alemany, R., et al. (2000). A mutant oncolytic adenovirus targeting the RB pathway produces anti-glioma effect in vivo. Oncogene, 19, 2–12.
Bischoff, J. R., Kirn, D. H., Williams, A., et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274, 373–376.
Khuri, F. R., Nemunaitis, J., Ganly, I., et al. (2000). A controlled trial of intratumoral onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine, 6, 879–885.
Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., & Kirn, D. H. (1997). Onyx-015, an e1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine, 3, 639–645.
Fults, D., Brockmeyer, D., Tullous, M. W., Pedone, C. A., & Cawthon, R. M. (1992). P53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Research, 52, 674–679.
Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., & Louis, D. N. (1996). Cdkn2/p16 or rb alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Research, 56, 150–153.
Chiocca, E. A., Abbed, K. M., Tatter, S., et al. (2004). A phase i open-label, dose-escalation, multi-institutional trial of injection with an e1b-attenuated adenovirus, onyx-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Molecular Therapy, 10, 958–966.
van Beusechem, V. W., Grill, J., Mastenbroek, D. C., et al. (2002). Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. The Journal of Virology, 76, 2753–2762.
Miller, C. R., Buchsbaum, D. J., Reynolds, P. N., et al. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research, 58, 5738–5748.
Fueyo, J., Alemany, R., Gomez-Manzano, C., et al. (2003). Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. Journal of the National Cancer Institute, 95, 652–660.
Bergelson, J. M., Cunningham, J. A., Droguett, G., et al. (1997). Isolation of a common receptor for coxsackie b viruses and adenoviruses 2 and 5. Science, 275, 1320–1323.
Tomko, R. P., Xu, R., & Philipson, L. (1997). Hcar and mcar: The human and mouse cellular receptors for subgroup c adenoviruses and group b coxsackieviruses. Proceedings of the National Academy of Sciences of the United States of America, 94, 3352–3356.
Asaoka, K., Tada, M., Sawamura, Y., Ikeda, J., & Abe, H. (2000). Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. Journal of Neurosurgery, 92, 1002–1008.
Grill, J., Van Beusechem, V. W., Van Der Valk, P., et al. (2001). Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clinical Cancer Research, 7, 641–650.
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987). Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proceedings of the National Academy of Sciences of the United States of America, 84, 6899–6903.
Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991). Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Research, 51, 2164–2172.
Hu, P., Margolis, B., Skolnik, E. Y., Lammers, R., Ullrich, A., & Schlessinger, J. (1992). Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Molecular and Cellular Biology, 12, 981–990.
Li, E., Stupack, D., Klemke, R., Cheresh, D. A., & Nemerow, G. R. (1998). Adenovirus endocytosis via alpha(v) integrins requires phosphoinositide-3-oh kinase. The Journal of Virology, 72, 2055–2061.
Wang, W., Zhu, N. L., Chua, J., et al. (2005). Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. Journal of Neurosurgery, 103, 1058–1066.
Kambara, H., Okano, H., Chiocca, E. A., & Saeki, Y. (2005). An oncolytic hsv-1 mutant expressing icp34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Research, 65, 2832–2839.
Vandier, D., Rixe, O., Besnard, F., et al. (2000). Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Therapy, 7, 1120–1126.
Shinoura, N., Saito, K., Yoshida, Y., et al. (2000). Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas. Cancer Gene Therapy, 7, 739–748.
Kohno, S., Nakagawa, K., Hamada, K., et al. (2004). Midkine promoter-based conditionally replicative adenovirus for malignant glioma therapy. Oncology Reports, 12, 73–78.
Parr, M. J., Manome, Y., Tanaka, T., et al. (1997). Tumor-selective transgene expression in vivo mediated by an e2f-responsive adenoviral vector. Nature Medicine, 3, 1145–1149.
Wilcox, M. E., Yang, W., Senger, D., et al. (2001). Reovirus as an oncolytic agent against experimental human malignant gliomas. Journal of the National Cancer Institute, 293, 903–912.
Komata, T., Kondo, Y., Kanzawa, T., et al. (2001). Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Research, 61, 5796–5802.
Zhou, Y., Larsen, P. H., Hao, C., & Yong, V. W. (2002). Cxcr4 is a major chemokine receptor on glioma cells and mediates their survival. The Journal of Biological Chemistry, 277, 49481–49487.
Oh, J. W., Drabik, K., Kutsch, O., Choi, C., Tousson, A., & Benveniste, E. N. (2001). Cxc chemokine receptor 4 expression and function in human astroglioma cells. The Journal of Immunology, 166, 2695–2704.
Mishima, K., Asai, A., Kadomatsu, K., et al. (1997). Increased expression of midkine during the progression of human astrocytomas. Neuroscience Letter, 233, 29–32.
Yang, L., Cao, Z., Li, F., et al. (2004). Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Therapy, 11, 1215–1223.
Post, D. E., & Van Meir, E. G. (2003). A novel hypoxia-inducible factor (hif) activated oncolytic adenovirus for cancer therapy. Oncogene, 22, 2065–2072.
Harada, K., Kurisu, K., Tahara, H., Tahara, E., & Ide, T. (2000). Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. Journal of Neurosurgery, 93, 618–625.
Alonso, M. M., Cascallo, M., Gomez-Manzano, C., et al. (2007). Icovir-5 shows e2f1 addiction and potent antiglioma effect in vivo. Cancer Research, 67, 8255–8263.
Yazaki, T., Manz, H. J., Rabkin, S. D., & Martuza, R. L. (1995). Treatment of human malignant meningiomas by g207, a replication-competent multimutated herpes simplex virus 1. Cancer Research, 55, 4752–4756.
Marcato, P., Dean, C. A., Giacomantonio, C. A., & Lee, P. W. (2009). Oncolytic reovirus effectively targets breast cancer stem cells. Molecular Therapy, 17, 972–979.
Zhang, X., Komaki, R., Wang, L., Fang, B., & Chang, J. Y. (2008). Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clinical Cancer Research, 14, 2813–2823.
Jiang, H., Gomez-Manzano, C., Aoki, H., et al. (2007). Examination of the therapeutic potential of delta-24-rgd in brain tumor stem cells: role of autophagic cell death. Journal of the National Cancer Institute, 99, 1410–1414.
Bao, S., Wu, Q., Li, Z., et al. Targeting cancer stem cells through l1cam suppresses glioma growth. Cancer Research, 68, 6043–6048.
Wakimoto, H., Kesari, S., Farrell, C. J., et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Research, 69, 3472–3481.
Van Houdt, W. J., Haviv, Y. S., Lu, B., et al. (2006). A novel transcriptional targeting strategy for treatment of glioma. Journal of Neurosurgery, 104, 583–592.
Ulasov, I. V., Rivera, A. A., Sonabend, A. M., et al. (2007). Comparative evaluation of survivin, midkine and cxcr4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biology and Therapy, 6, 679–685.
Ulasov, I. V., Zhu, Z. B., Tyler, M. A., et al. (2007). Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Human Gene Therapy, 18, 589–602.
Nandi, S., Ulasov, I. V., Tyler, M. A., et al. (2008). Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Research, 68, 5778–5784.
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death and Differention, 11, 448–457.
Shmelkov, S. V., Jun, L., St Clair, R., et al. (2004). Alternative promoters regulate transcription of the gene that encodes stem cell surface protein ac133. Blood, 103, 2055–2061.
Bleehen, N. M., & Stenning, S. P. (1991). A medical research council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The medical research council brain tumour working party. British Journal of Cancer, 64, 769–774.
Stewart, L. A. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359, 1011–1018.
Westphal, M., Hilt, D. C., Bortey, E., et al. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (bcnu) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro Oncology, 5, 79–88.
Acknowledgements/Conflict of Interest
This work was supported by the National Cancer Institute (R01-CA122930, R01-CA138587, R21-CA135728), the National Institute of Neurological Disorders and Stroke (K08-NS046430), The Alliance for Cancer Gene Therapy Young Investigator Award, and the American Cancer Society (RSG-07-276-01-MGO).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dey, M., Ulasov, I.V., Tyler, M.A. et al. Cancer Stem Cells: The Final Frontier for Glioma Virotherapy. Stem Cell Rev and Rep 7, 119–129 (2011). https://doi.org/10.1007/s12015-010-9132-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12015-010-9132-7